Cellular Oncology

, Volume 36, Issue 6, pp 439–448 | Cite as

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer

  • Paola UliviEmail author
  • Rosella Silvestrini



The release of DNA into peripheral blood is a common event in cancer patients, occurring as a consequence of necrotic and apoptotic processes typical of tumor cells. However, free circulating DNA (fcDNA) is also present in patients with benign diseases and in healthy individuals. Both quantitative and qualitative aspects of fcDNA have been studied as potential biomarkers in a number of tumor types. In particular, quantitative analysis of fcDNA has been shown to play an important role in the diagnosis of non-small cell lung cancer (NSCLC), because of its ability to discriminate between healthy subjects and individuals with NSCLC. Additionally, fcDNA in cancer patients derives predominantly from tumor tissue and, as such, it can be used for the molecular characterization of the primary tumor. Targeted therapies in NSCLC have, in recent years, produced promising results, highlighting the importance of molecular profiling of the primary cancer lesions. Considering that little or no tumor material is available for at least some of the patients, the possibility of using fcDNA for molecular analysis becomes increasingly important. In the present review we evaluated several quantitative and qualitative aspects of fcDNA that could be instrumental for the differential diagnosis of lung disease.


There is ample evidence in the literature to support the possible use of peripheral blood-derived fcDNA in the early diagnosis and molecular characterization of lung cancer. This non-invasive method may also turn out to be valuable in monitoring drug response and in identifying induced mechanisms of drug resistance. Before it can be implemented in routine clinical practice, however, additional efforts are needed to standardize the methodology.


fcDNA Serum Plasma Diagnosis Mutation Lung cancer 



The authors would like to thank Ursula Elbling for editing the manuscript.

Conflict of interest

The authors have no conflicts of interest to declare.


  1. 1.
    R. Swaminathan, A.N. Butt, Circulating nucleic acids in plasma and serum: recent developments. Ann. N. Y. Acad. Sci. 1075, 1–9 (2006)PubMedGoogle Scholar
  2. 2.
    K. Jung, M. Fleischhacker, A. Rabien, Cell-free DNA in the blood as a solid tumor biomarker- a critical appraisal of the literatue. Clin. Chim. Acta 411(21–22), 1611–1624 (2010)PubMedGoogle Scholar
  3. 3.
    A. Ziegler, U. Zangemeister-Wittke, R.A. Stahel, Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 28(5), 255–271 (2002)PubMedGoogle Scholar
  4. 4.
    N. Suzuki, A. Kamataki, J. Yamaki, Y. Homma, Characterization of circulating DNA in healthy human plasma. Clin. Chim. Acta 387(1–2), 55–58 (2008)PubMedGoogle Scholar
  5. 5.
    M. Stroun, P. Maurice, V. Vasioukhin, J. Lyautey, C. Lederrey, F. Lefort, A. Rossier, X.Q. Chen, P. Anker, The origin and mechanism of circulating DNA. Ann. N. Y. Acad. Sci. 906, 161–168 (2000)PubMedGoogle Scholar
  6. 6.
    M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, P. Anker, About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313(1–2), 139–142 (2001)PubMedGoogle Scholar
  7. 7.
    C.N. Li, H.L. Hsu, T.L. Wu, K.C. Tsao, C.F. Sun, J.T. Wu, Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J. Clin. Lab. Anal. 17(4), 103–107 (2003)PubMedGoogle Scholar
  8. 8.
    D.C. García-Olmo, J. Samos, M.G. Picazo, A.I. Asensio, I. Toboso, D. García-Olmo, Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 272(1), 133–140 (2008)PubMedGoogle Scholar
  9. 9.
    H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, M. Widschwendter, Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 65(4), 1141–1145 (2005)PubMedGoogle Scholar
  10. 10.
    A. Altimari, A.D. Grigioni, E. Benedettini, E. Gabusi, R. Schiavina, A. Martinelli, A.M. Morselli-Labate, G. Martorana, W.F. Grigioni, M. Fiorentino, Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol. 129(5), 756–762 (2008)PubMedGoogle Scholar
  11. 11.
    P.J. Bastian, G.S. Palapattu, S. Yegnasubramanian, X. Lin, C.G. Rogers, L.A. Mangold, B. Trock, M. Eisenberger, A.W. Partin, W.G. Nelson, Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin. Cancer Res. 13(18 Pt 1), 5361–5367 (2007)PubMedGoogle Scholar
  12. 12.
    E. Papadopoulou, E. Davilas, V. Sotiriou, E. Georgakopoulos, S. Georgakopoulou, A. Koliopanos, F. Aggelakis, K. Dardoufas, N.J. Agnanti, I. Karydas, G. Nasioulas, Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 1075, 235–243 (2006)PubMedGoogle Scholar
  13. 13.
    K. Jung, C. Stephan, M. Lewandowski, S. Klotzek, M. Jung, G. Kristiansen, M. Lein, S.A. Loening, D. Schnorr, Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 205(2), 173–180 (2004)PubMedGoogle Scholar
  14. 14.
    X.Y. Zhong, A. Ladewig, S. Schmid, E. Wight, S. Hahn, W. Holzgreve, Elevated level of cell-free plasma DNA is associated with breast cancer. Arch. Gynecol. Obstet. 276(4), 327–331 (2007)PubMedGoogle Scholar
  15. 15.
    C. Kohler, R. Radpour, Z. Barekati, R. Asadollahi, J. Bitzer, E. Wight, N. Bürki, C. Diesch, W. Holzgreve, X.Y. Zhong, Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer 8, 105 (2009)PubMedGoogle Scholar
  16. 16.
    H. Schwarzenbach, V. Müller, N. Stahmann, K. Pantel, Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. N. Y. Acad. Sci. 1022, 25–32 (2004)PubMedGoogle Scholar
  17. 17.
    G. Sozzi, D. Conte, M. Leon, R. Ciricione, L. Roz, C. Ratcliffe, E. Roz, N. Cirenei, M. Bellomi, G. Pelosi, M.A. Pierotti, U. Pastorino, Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21(21), 3902–3908 (2003)PubMedGoogle Scholar
  18. 18.
    P. Ulivi, L. Mercatali, W. Zoli, D. Dell’amore, V. Poletti, G.L. Casoni, E. Scarpi, E. Flamini, D. Amadori, R. Silvestrini, Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax 63(9), 843–844 (2008)PubMedGoogle Scholar
  19. 19.
    E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G.M. Verdecchia, D. Amadori, Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin. Cancer Res. 12(23), 6985–6988 (2006)PubMedGoogle Scholar
  20. 20.
    R. Catarino, M.M. Ferreira, H. Rodrigues, A. Coelho, A. Nogal, A. Sousa, R. Medeiros, Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 27(8), 415–421 (2008)PubMedGoogle Scholar
  21. 21.
    C.P. Chang, R.H. Chia, T.L. Wu, K.C. Tsao, C.F. Sun, J.T. Wu, Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin. Chim. Acta 327(1–2), 95–101 (2003)PubMedGoogle Scholar
  22. 22.
    G.J. Fournié, F. Martres, J.P. Pourrat, C. Alary, M. Rumeau, Plasma DNA as cell death marker in elderly patients. Gerontology 39(4), 215–221 (1993)PubMedGoogle Scholar
  23. 23.
    T.H. Rainer, N.Y. Lam, Circulating nucleic acids and critical illness. Ann. N. Y. Acad. Sci. 1075, 271–277 (2006)PubMedGoogle Scholar
  24. 24.
    J.M. Silva, J. Silva, A. Sanchez, J.M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareño, A. Colas, P. España, F. Bonilla, Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8(12), 3761–3766 (2002)PubMedGoogle Scholar
  25. 25.
    N. Ren, Q.H. Ye, L.X. Qin, B.H. Zhang, Y.K. Liu, Z.Y. Tang, Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J. Gastroenterol. 12(24), 3911–3914 (2006)PubMedGoogle Scholar
  26. 26.
    O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, E. Chassé, D. Ratschiller, W. Weder, M. Joerger, D.C. Betticher, R.A. Stahel, A. Ziegler, Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 22(20), 4157–4164 (2004)PubMedGoogle Scholar
  27. 27.
    A.A. Kamat, M. Baldwin, D. Urbauer, D. Dang, L.Y. Han, A. Godwin, B.Y. Karlan, J.L. Simpson, D.M. Gershenson, R.L. Coleman, F.Z. Bischoff, A.K. Sood, Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116(8), 1918–1925 (2010)PubMedGoogle Scholar
  28. 28.
    Z.H. Huang, L.H. Li, D. Hua, Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 243(1), 64–70 (2006)PubMedGoogle Scholar
  29. 29.
    M. Frattini, G. Gallino, S. Signoroni, D. Balestra, L. Lusa, L. Battaglia, G. Sozzi, L. Bertario, E. Leo, S. Pilotti, M.A. Pierotti, Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 263(2), 170–181 (2008)PubMedGoogle Scholar
  30. 30.
    F. Banki, R.J. Mason, D. Oh, J.A. Hagen, S.R. DeMeester, J.C. Lipham, K. Tanaka, K.D. Danenberg, W.N. Yacoub, P.V. Danenberg, T.R. DeMeester, Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch. Surg. 142(6), 533–538 (2007)PubMedGoogle Scholar
  31. 31.
    R.A. Perego, M. Corizzato, P. Brambilla, S. Ferrero, C. Bianchi, E. Fasoli, S. Signorini, B. Torsello, L. Invernizzi, S. Bombelli, V. Angeloni, M. Pitto, C. Battaglia, V. Proserpio, F. Magni, G. Galasso, P. Mocarelli, Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur. J. Cancer 44(7), 1039–1047 (2008)PubMedGoogle Scholar
  32. 32.
    G. Sozzi, D. Conte, L. Mariani, S. Lo Vullo, L. Roz, C. Lombardo, M.A. Pierotti, L. Tavecchio, Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61(12), 4675–4678 (2001)PubMedGoogle Scholar
  33. 33.
    B.G. Wang, H.Y. Huang, Y.C. Chen, R.E. Bristow, K. Kassauei, C.C. Cheng, R. Roden, L.J. Sokoll, D.W. Chan, S. IeM, Increased plasma DNA integrity in cancer patients. Cancer Res. 63(14), 3966–3968 (2003)PubMedGoogle Scholar
  34. 34.
    N. Umetani, J. Kim, S. Hiramatsu, H.A. Reber, O.J. Hines, A.J. Bilchik, D.S. Hoon, Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 52(6), 1062–1069 (2006)PubMedGoogle Scholar
  35. 35.
    N. Umetani, A.E. Giuliano, S.H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, D.S. Hoon, Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 24(26), 4270–4276 (2006)PubMedGoogle Scholar
  36. 36.
    R. Hanley, K.M. Rieger-Christ, D. Canes, N.R. Emara, A.P. Shuber, K.A. Boynton, J.A. Libertino, I.C. Summerhayes, DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin. Cancer Res. 12(15), 4569–4574 (2006)PubMedGoogle Scholar
  37. 37.
    H. Tomita, D. Ichikawa, D. Ikoma, S. Sai, N. Tani, H. Ikoma, H. Fujiwara, S. Kikuchi, K. Okamoto, T. Ochiai, E. Otsuji, Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 27(4C), 2737–2741 (2007)PubMedGoogle Scholar
  38. 38.
    W.W. Jiang, M. Zahurak, D. Goldenberg, Y. Milman, H.L. Park, W.H. Westra, W. Koch, D. Sidransky, J. Califano, Increased plasma DNA integrity index in head and neck cancer patients. Int. J. Cancer 119(11), 2673–2676 (2006)PubMedGoogle Scholar
  39. 39.
    B. Schmidt, S. Weickmann, C. Witt, M. Fleischhacker, Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann. N. Y. Acad. Sci. 1137, 207–213 (2008)PubMedGoogle Scholar
  40. 40.
    S. Holdenrieder, A. Burges, O. Reich, F.W. Spelsberg, P. Stieber, DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann. N. Y. Acad. Sci. 1137, 162–170 (2008)PubMedGoogle Scholar
  41. 41.
    E. Gormally, P. Vineis, G. Matullo, F. Veglia, E. Caboux, E. Le Roux, M. Peluso, S. Garte, S. Guarrera, A. Munnia, L. Airoldi, H. Autrup, C. Malaveille, A. Dunning, K. Overvad, A. Tjønneland, E. Lund, F. Clavel-Chapelon, H. Boeing, A. Trichopoulou, D. Palli, V. Krogh, R. Tumino, S. Panico, H.B. Bueno-de-Mesquita, P.H. Peeters, G. Pera, C. Martinez, M. Dorronsoro, A. Barricarte, C. Navarro, J.R. Quirós, G. Hallmans, N.E. Day, T.J. Key, R. Saracci, R. Kaaks, E. Riboli, P. Hainaut, TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66(13), 6871–6876 (2006)PubMedGoogle Scholar
  42. 42.
    Z.M. Shao, J. Wu, Z.Z. Shen, M. Nguyen, p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin. Cancer Res. 7(8), 2222–2227 (2001)PubMedGoogle Scholar
  43. 43.
    T. Ito, K. Kaneko, R. Makino, K. Konishi, T. Kurahashi, H. Ito, A. Katagiri, M. Kushima, M. Kusano, K. Mitamura, M. Imawari, Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma. Oncol. Rep. 10(6), 1937–1942 (2003)PubMedGoogle Scholar
  44. 44.
    T. Kimura, W.S. Holland, T. Kawaguchi, S.K. Williamson, K. Chansky, J.J. Crowley, J.H. Doroshow, H.J. Lenz, D.R. Gandara, P.H. Gumerlock, Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann. N. Y. Acad. Sci. 1022, 55–60 (2004)PubMedGoogle Scholar
  45. 45.
    J. Däbritz, J. Hänfler, R. Preston, J. Stieler, H. Oettle, Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br. J. Cancer 92(2), 405–412 (2005)PubMedGoogle Scholar
  46. 46.
    R.E. Board, L. Knight, A. Greystoke, F.H. Blackhall, A. Hughes, C. Dive, M. Ranson, Biomark. Insights 2, 307–319 (2007)Google Scholar
  47. 47.
    G.S. Xie, A.R. Hou, L.Y. Li, Y.N. Gao, S.J. Cheng, Quantification of plasma DNA as a screening tool for lung cancer. Chin. Med. J. (Engl.) 117(10), 1485–1488 (2004)Google Scholar
  48. 48.
    L.J. Herrera, S. Raja, W.E. Gooding, T. El-Hefnawy, L. Kelly, J.D. Luketich, T.E. Godfrey, Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin. Chem. 51(1), 113–118 (2005)PubMedGoogle Scholar
  49. 49.
    V. Ludovini, L. Pistola, V. Gregorc, I. Floriani, E. Rulli, S. Piattoni, L. Di Carlo, A. Semeraro, S. Darwish, F.R. Tofanetti, L. Stocchi, Z. Mihaylova, G. Bellezza, R. Del Sordo, G. Daddi, L. Crinò, M. Tonato, Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J. Thorac. Oncol. 3(4), 365–373 (2008)PubMedGoogle Scholar
  50. 50.
    M. Paci, S. Maramotti, E. Bellesia, D. Formisano, L. Albertazzi, T. Ricchetti, G. Ferrari, V. Annessi, D. Lasagni, C. Carbonelli, S. De Franco, M. Brini, G. Sgarbi, R. Lodi, Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64(1), 92–97 (2009)PubMedGoogle Scholar
  51. 51.
    K.A. Yoon, S. Park, S.H. Lee, J.H. Kim, J.S. Lee, Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. Mol. Diagn. 11(3), 182–185 (2009)Google Scholar
  52. 52.
    A. Szpechcinski, M. Dancewicz, P. Kopinski, J. Kowalewski, J. Chorostowska-Wynimko, Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur. J. Med. Res. 14(Suppl 4), 237–240 (2009)PubMedGoogle Scholar
  53. 53.
    S. Kumar, R. Guleria, V. Singh, A.C. Bharti, A. Mohan, B.C. Das, Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 70(2), 211–217 (2010)PubMedGoogle Scholar
  54. 54.
    A. Szpechcinski, J. Chorostowska-Wynimko, W. Kupis, K. Maszkowska-Kopij, M. Dancewicz, J. Kowalewski, T. Orlowski, Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin. Biol. 12(Suppl 1), S3–S9 (2012)Google Scholar
  55. 55.
    R. Catarino, A. Coelho, A. Araújo, M. Gomes, A. Nogueira, C. Lopes, R. Medeiros, Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 7(6), e38559 (2012)PubMedGoogle Scholar
  56. 56.
    P. Ulivi, L. Mercatali, G.L. Casoni, E. Scarpi, L. Bucchi, R. Silvestrini, S. Sanna, M. Monteverde, D. Amadori, V. Poletti, W. Zoli, Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One 8(2), e57401 (2013)PubMedGoogle Scholar
  57. 57.
    R. Zhang, F. Shao, X. Wu, K. Ying, Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69(2), 225–231 (2010)PubMedGoogle Scholar
  58. 58.
    R. Rami-Porta, D. Ball, J. Crowley, D.J. Giroux, J. Jett, W.D. Travis, M. Tsuboi, E. Vallières, P. Goldstraw, International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions, The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 2(7), 593–602 (2007)PubMedGoogle Scholar
  59. 59.
    Y. Saito, N. Nagamoto, S. Ota, M. Sato, M. Sagawa, K. Kamma, S. Takahashi, K. Usuda, C. Endo, T. Imai, Results of surgical treatment for roentgenographically occult bronchogenic squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 104(2), 401–407 (1992)PubMedGoogle Scholar
  60. 60.
    G. Sozzi, L. Roz, D. Conte, L. Mariani, F. Andriani, S. Lo Vullo, C. Verri, U. Pastorino, Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am. J. Respir. Crit. Care Med. 179(1), 69–74 (2009)PubMedGoogle Scholar
  61. 61.
    G.L. Casoni, P. Ulivi, L. Mercatali, M. Chilosi, S. Tomassetti, M. Romagnoli, C. Ravaglia, C. Gurioli, C. Gurioli, W. Zoli, R. Silvestrini, V. Poletti, Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. Int. J. Biol. Markers 25(4), 229–235 (2010)PubMedGoogle Scholar
  62. 62.
    R. Sirera, R.M. Bremnes, A. Cabrera, E. Jantus-Lewintre, E. Sanmartìn, A. Blasco, N. del Pozo, R. Rosell, R. Guijarro, J. Galbis, J.J. Sànchez, C. Camps, Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6(2), 286–290 (2011)PubMedGoogle Scholar
  63. 63.
    M.A. van der Drift, B.E. Hol, C.H. Klaassen, C.F. Prinsen, Y.A. van Aarssen, R. Donders, J.W. van der Stappen, P.N. Dekhuijzen, H.F. van der Heijden, F.B. Thunnissen, Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68(2), 283–287 (2010)PubMedGoogle Scholar
  64. 64.
    A.K. Pathak, M. Bhutani, S. Kumar, A. Mohan, R. Guleria, Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin. Chem. 52(10), 1833–1842 (2006)PubMedGoogle Scholar
  65. 65.
    M. Beau-Faller, M.P. Gaub, A. Schneider, X. Ducrocq, G. Massard, B. Gasser, M.P. Chenard, R. Kessler, P. Anker, M. Strounm, E. Weitzenblum, G. Pauli, J.M. Wihlm, E. Quoix, P. Oudet, Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int. J. Cancer 105(3), 361–370 (2003)PubMedGoogle Scholar
  66. 66.
    Y.J. Lee, K.A. Yoon, J.Y. Han, H.T. Kim, T. Yun, G.K. Lee, H.Y. Kim, J.S. Lee, Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin. Cancer Res. 17(15), 5179–5187 (2011)PubMedGoogle Scholar
  67. 67.
    M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin, J.G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67–70 (1999)PubMedGoogle Scholar
  68. 68.
    A. Bearzatto, D. Conte, M. Frattini, N. Zaffaroni, F. Andriani, D. Balestra, L. Tavecchio, M.G. Daidone, G. Sozzi, p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin. Cancer Res. 8(12), 3782–3787 (2002)PubMedGoogle Scholar
  69. 69.
    Y. Liu, Q. An, L. Li, D. Zhang, J. Huang, X. Feng, S. Cheng, Y. Gao, Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24(12), 1897–1901 (2003)PubMedGoogle Scholar
  70. 70.
    P. Ulivi, W. Zoli, D. Calistri, F. Fabbri, A. Tesei, M. Rosetti, M. Mengozzi, D. Amadori, p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J. Cell. Physiol. 206(3), 611–615 (2006)PubMedGoogle Scholar
  71. 71.
    K. Fujiwara, N. Fujimoto, M. Tabata, K. Nishii, K. Matsuo, K. Hotta, T. Kozuki, M. Aoe, K. Kiura, H. Ueoka, M. Tanimoto, Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 11(3), 1219–1225 (2005)PubMedGoogle Scholar
  72. 72.
    H.S. Hsu, T.P. Chen, C.H. Hung, C.K. Wen, R.K. Lin, H.C. Lee, Y.C. Wang, Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110(9), 2019–2026 (2007)PubMedGoogle Scholar
  73. 73.
    K.L. Ostrow, M.O. Hoque, M. Loyo, M. Brait, A. Greenberg, J.M. Siegfried, J.R. Grandis, A. Gaither Davis, W.L. Bigbee, W. Rom, D. Sidransky, Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin. Cancer Res. 16(13), 3463–3472 (2010)PubMedGoogle Scholar
  74. 74.
    Y. Zhang, R. Wang, H. Song, G. Huang, J. Yi, Y. Zheng, J. Wang, L. Chen, Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303(1), 21–28 (2011)PubMedGoogle Scholar
  75. 75.
    S. Begum, M. Brait, S. Dasgupta, K.L. Ostrow, M. Zahurak, A.L. Carvalho, J.A. Califano, S.N. Goodman, W.H. Westra, M.O. Hoque, D. Sidransky, An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494–4503 (2011)PubMedGoogle Scholar
  76. 76.
    K. Woodson, J. Mason, S.W. Choi, T. Hartman, J. Tangrea, J. Virtamo, P.R. Taylor, D. Albanes, Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol. Biomarkers Prev. 10(1), 69–74 (2001)PubMedGoogle Scholar
  77. 77.
    T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009)PubMedGoogle Scholar
  78. 78.
    R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, L. Paz-Ares, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie, Associazione Italiana Oncologia Toracica, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(13), 239–246 (2012)PubMedGoogle Scholar
  79. 79.
    P. Ulivi, W. Zoli, E. Chiadini, L. Capelli, P. Candoli, D. Calistri, R. Silvestrini, M. Puccetti, EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients. Eur. Respir. J. 40(1), 267–269 (2012)PubMedGoogle Scholar
  80. 80.
    J.H. Smouse, E.S. Cibas, P.A. Jänne, V.A. Joshi, K.H. Zou, N.I. Lindeman, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 117(1), 67–72 (2009)PubMedGoogle Scholar
  81. 81.
    S. Savic, C. Tapia, B. Grilli, A. Rufle, M.P. Bihl, A. de Vito Barascud, M. Herzog, L. Terracciano, F. Baty, L. Bubendorf, Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br. J. Cancer 98(1), 154–160 (2008)PubMedGoogle Scholar
  82. 82.
    S. Maheswaran, L.V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C.V. Collura, E. Inserra, S. Diederichs, A.J. Iafrate, D.W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R.G. Tompkins, T.J. Lynch, M. Toner, D.A. Haber, Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366–377 (2008)PubMedGoogle Scholar
  83. 83.
    H. Kimura, M. Suminoe, K. Kasahara, T. Sone, T. Araya, S. Tamori, F. Koizumi, K. Nishio, K. Miyamoto, M. Fujimura, S. Nakao, Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br. J. Cancer 97(6), 778–784 (2007)PubMedGoogle Scholar
  84. 84.
    T.K. Yung, K.C. Chan, T.S. Mok, J. Tong, K.F. To, Y.M. Lo, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin. Cancer Res. 15(6), 2076–2084 (2009)PubMedGoogle Scholar
  85. 85.
    Y. Kuang, A. Rogers, B.Y. Yeap, L. Wang, M. Makrigiorgos, K. Vetrand, S. Thiede, R.J. Distel, P.A. Jänne, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15(8), 2630–2636 (2009)PubMedGoogle Scholar
  86. 86.
    C. He, M. Liu, C. Zhou, J. Zhang, M. Ouyang, N. Zhong, J. Xu, Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int. J. Cancer 125(10), 2393–2399 (2009)PubMedGoogle Scholar
  87. 87.
    H. Bai, L. Mao, H.S. Wang, J. Zhao, L. Yang, T.T. An, X. Wang, C.J. Duan, N.M. Wu, Z.Q. Guo, Y.X. Liu, H.N. Liu, Y.Y. Wang, J. Wang, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol. 27(16), 2653–2659 (2009)PubMedGoogle Scholar
  88. 88.
    P.C. Mack, W.S. Holland, R.A. Burich, R. Sangha, L.J. Solis, Y. Li, L.A. Beckett, P.N. Jr Lara, A.M. Davies, D.R. Gandara, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J. Thorac. Oncol. 4(12), 1466–1472 (2009)PubMedGoogle Scholar
  89. 89.
    B. Jiang, F. Liu, L. Yang, W. Zhang, H. Yuan, J. Wang, G. Huang, Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J. Int. Med. Res. 39(4), 1392–1401 (2011)PubMedGoogle Scholar
  90. 90.
    M. Brevet, M.L. Johnson, C.G. Azzoli, M. Ladanyi, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73(1), 96–102 (2011)PubMedGoogle Scholar
  91. 91.
    K. Taniguchi, J. Uchida, K. Nishino, T. Kumagai, T. Okuyama, J. Okami, M. Higashiyama, K. Kodama, F. Imamura, K. Kato, Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17(24), 7808–7815 (2011)PubMedGoogle Scholar
  92. 92.
    Y.M. Chen, W.C. Fan, P.C. Tseng, C.M. Tsai, T.Y. Chou, C.H. Wu, K.T. Chou, Y.C. Lee, R.P. Perng, J. Whang-Peng, Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncol. Lett. 3(3), 713–717 (2012)PubMedGoogle Scholar
  93. 93.
    T. Nakamura, N. Sueoka-Aragane, K. Iwanaga, A. Sato, K. Komiya, N. Kobayashi, S. Hayashi, T. Hosomi, M. Hirai, E. Sueoka, S. Kimura, Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J. Thorac. Oncol. 7(9), 1369–1381 (2012)PubMedGoogle Scholar
  94. 94.
    K. Goto, Y. Ichinose, Y. Ohe, N. Yamamoto, S. Negoro, K. Nishio, Y. Itoh, H. Jiang, E. Duffield, R. McCormack, N. Saijo, T. Mok, M. Fukuoka, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J. Thorac. Oncol. 7(1), 115–121 (2012)PubMedGoogle Scholar
  95. 95.
    E.A. Punnoose, S. Atwal, W. Liu, R. Raja, B.M. Fine, B.G. Hughes, R.J. Hicks, G.M. Hampton, L.C. Amler, A. Pirzkall, M.R. Lackner, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18(8), 2391–2401 (2012)PubMedGoogle Scholar
  96. 96.
    X. Zhao, R.B. Han, J. Zhao, J. Wang, F. Yang, W. Zhong, L. Zhang, L.Y. Li, M.Z. Wang, Comparison of Epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV Non-small cell lung cancer patients. Respiration 85(2), 119–125 (2013)PubMedGoogle Scholar
  97. 97.
    S. Wang, T. An, J. Wang, J. Zhao, Z. Wang, M. Zhuo, H. Bai, L. Yang, Y. Zhang, X. Wang, J. Duan, Y. Wang, Q. Guo, M. Wu, Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16(4), 1324–1330 (2010)PubMedGoogle Scholar
  98. 98.
    F. Andriani, D. Conte, T. Mastrangelo, M. Leon, C. Ratcliffe, L. Roz, G. Pelosi, P. Goldstraw, G. Sozzi, U. Pastorino, Detecting lung cancer in plasma with the use of multiple genetic markers. Int. J. Cancer 108(1), 91–96 (2004)PubMedGoogle Scholar
  99. 99.
    G. Sozzi, K. Musso, C. Ratcliffe, P. Goldstraw, M.A. Pierotti, U. Pastorino, Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5(10), 2689–2692 (1999)PubMedGoogle Scholar
  100. 100.
    N. Bruhn, T. Beinert, C. Oehm, B. Jandrig, I. Petersen, X.Q. Chen, K. Possinger, M. Fleischhacker, Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann. N. Y. Acad. Sci. 906, 72–82 (2000)PubMedGoogle Scholar
  101. 101.
    M.A. Thijssen, D.W. Swinkels, T.J. Ruers, J.B. de Kok, Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 22(1A), 421–425 (2002)PubMedGoogle Scholar
  102. 102.
    Y.Y. Lui, K.W. Chik, R.W. Chiu, C.Y. Ho, C.W. Lam, Y.M. Lo, Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48(3), 421–427 (2002)PubMedGoogle Scholar
  103. 103.
    M. Jung, S. Klotzek, M. Lewandowski, M. Fleischhacker, K. Jung, Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin. Chem. 49(6 Pt 1), 1028–1029 (2003)PubMedGoogle Scholar
  104. 104.
    T.H. Lee, L. Montalvo, V. Chrebtow, M.P. Busch, Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41(2), 276–282 (2001)PubMedGoogle Scholar
  105. 105.
    J. Jen, L. Wu, D. Sidransky, An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann. N. Y. Acad. Sci. 906, 8–12 (2000)PubMedGoogle Scholar
  106. 106.
    Y.Y. Lui, K.W. Chik, Y.M. Lo, Does centrifugation cause the ex vivo release of DNA from blood cells? Clin. Chem. 48(11), 2074–2076 (2002)PubMedGoogle Scholar
  107. 107.
    X. Xue, M.D. Teare, I. Holen, Y.M. Zhu, P.J. Woll, Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin. Chim. Acta 404(2), 100–104 (2009)PubMedGoogle Scholar
  108. 108.
    G. Sozzi, L. Roz, D. Conte, L. Mariani, F. Andriani, P. Verderio, U. Pastorino, Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J. Natl. Cancer Inst. 97(24), 1848–1850 (2005)PubMedGoogle Scholar
  109. 109.
    J.B. de Kok, J.C. Hendriks, W.W. van Solinge, H.L. Willems, E.J. Mensink, D.W. Swinkels, Use of real-time quantitative PCR to compare DNA isolation methods. Clin. Chem. 44(10), 2201–2204 (1998)PubMedGoogle Scholar
  110. 110.
    C. Stemmer, M. Beau-Faller, E. Pencreac’h, E. Guerin, A. Schneider, D. Jaqmin, E. Quoix, M.P. Gaub, P. Oudet, Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics. Clin. Chem. 49(11), 1953–1955 (2003)PubMedGoogle Scholar
  111. 111.
    B. Schmidt, S. Weickmann, C. Witt, M. Fleischhacker, Improved method for isolating cell-free DNA. Clin. Chem. 51(8), 1561–1563 (2005)PubMedGoogle Scholar
  112. 112.
    C.J. Jorgez, D.D. Dang, J.L. Simpson, D.E. Lewis, F.Z. Bischoff, Quantity versus quality: optimal methods for cell-free DNA isolation from plasma of pregnant women. Genet. Med. 8(10), 615–619 (2006)PubMedGoogle Scholar
  113. 113.
    S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, C.T. Wittwer, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55(4), 611–622 (2009)PubMedGoogle Scholar
  114. 114.
    J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin, S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93(18), 9821–9826 (1996)PubMedGoogle Scholar
  115. 115.
    C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg, P.W. Laird, MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000)PubMedGoogle Scholar
  116. 116.
    S.A. Qureshi, M.U. Bashir, A. Yaqinuddin, Utility of DNA methylation markers for diagnosing cancer. Int. J. Surg. 8(3), 194–198 (2010)PubMedGoogle Scholar
  117. 117.
    T. Tanaka, Y. Nagai, H. Miyazawa, N. Koyama, S. Matsuoka, A. Sutani, A. Huqun, K. Udagawa, Y. Murayama, M. Nagata, Y. Shimizu, K. Ikebuchi, M. Kanazawa, K. Kobayashi, K. Hagiwara, Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 98(2), 246–252 (2007)PubMedGoogle Scholar
  118. 118.
    H. Kimura, Y. Fujiwara, T. Sone, H. Kunitoh, T. Tamura, K. Kasahara, K. Nishio, High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 97(7), 642–648 (2006)PubMedGoogle Scholar
  119. 119.
    K.A. Heyries, C. Tropini, M. Vaninsberghe, C. Doolin, O.I. Petriv, A. Singhal, K. Leung, C.B. Hughesman, C.L. Hansen, Megapixel digital PCR. Nat. Methods 8(8), 649–651 (2011)PubMedGoogle Scholar
  120. 120.
    A. Narayan, N.J. Carriero, S.N. Gettinger, J. Kluytenaar, K.R. Kozak, T.I. Yock, N.E. Muscato, P. Ugarelli, R.H. Decker, A.A. Patel, Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72(14), 3492–3498 (2012)PubMedGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2013

Authors and Affiliations

  1. 1.Biosciences LaboratoryIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCSMeldolaItaly

Personalised recommendations